Zyflozin 10 Tablet contains Dapagliflozin 10 mg, an oral antihyperglycemic agent belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is primarily indicated for the management of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. Dapagliflozin acts by inhibiting SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering plasma glucose levels. This mechanism is independent of insulin secretion or action, making it effective in patients with insulin resistance. Zyflozin 10 may be used as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. Clinical studies have demonstrated its efficacy in reducing HbA1c levels, promoting weight loss, and lowering blood pressure. The medication is generally well-tolerated; however, potential adverse effects include urinary tract infections, genital mycotic infections, increased urination, and rare cases of ketoacidosis. It is contraindicated in patients with severe renal impairment, end-stage renal disease, or dialysis. Regular monitoring of renal function and glycemic parameters is recommended during therapy. Zyflozin 10 should be prescribed with caution in patients at risk of volume depletion or hypotension.